The authors would like to thank the participants in this study for their cooperation. We also would like to thank the nurse practitioners P.A. Ninaber, W.A.M. Janssen, W.H. van Zimmeren-Feijen, and heart failure nurse J.G. Froon-Elferink for their contribution to inclusion of participants and data collection. The authors owe much gratitude to the pulmonary function and clinical chemistry and hematology laboratories as well as the echocardiography and radiology departments for their assistance in data collection. Finally, we would like to acknowledge biostatistician A.R.T. Donders for his contribution to statistical analysis.
References
1. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail. 2008;14:695-702. 2. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004;125:669-82. 3. Mancini DM. Pulmonary factors limiting exercise capacity in patients with heart failure. Prog Cardiovasc
Dis. 1995;37:347-70.
4. Kindman LA, Vagelos RH, Willson K, Prikazky L, Fowler M. Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide. Am J Cardiol. 1994;73:258-62. 5. Ng TM, Munger MA, Lombardi WL, Doing TH, Ryujin DT, Young DC, et al. Chronically inhaled salmeterol
improves pulmonary function in heart failure. J Cardiovasc Pharmacol. 2002;40:140-5.
6. Rolla G, Bucca C, Brussino L, Gallo W, Malara D. Bronchodilating effect of ipratropium bromide in heart failure. Eur Respir J. 1993;6:1492-5.
7. Uren NG, Davies SW, Jordan SL, Lipkin DP. Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure. Eur Heart J. 1993;14:744-50.
8. Khan KA, Jalal S, Jan VM, Lone GM, Jan R, Alai MS, et al. Pulmonary function profile in chronic congestive heart failure and the effect of ipratropium bromide. Indian Heart J. 2000;52:297-300. 9. Kurzawa R, Baron T, Grodzicki T. Pulmonary function test abnormalities in the elderly with systolic
heart failure. Kardiol Pol. 2007;65:875-80. discussion 81-2.
10. Witte KK, Morice A, Cleland JG, Clark AL. The reversibility of increased airways resistance in chronic heart failure measured by impulse oscillometry. J Card Fail. 2004;10:149-54.
11. Harrington D, Chua TP, Coats AJ. The effect of salbutamol on skeletal muscle in chronic heart failure. Int J Cardiol. 2000;73:257-65.
12. Moore DP, Weston A, Hughes JM, Oakley CM, Cleland JG. Bronchial hyperresponsiveness in heart failure. N Engl J Med. 1993;328:1424-5.
13. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1983;143:429-33.
14. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Hassager C, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264:361-9.
15. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHBLI/WHO workshop report. Available at: http://www.goldcopd.org; 2010.
16. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442. 17. Global Initiative for asthma. Global strategy for asthma management and prevention. NHBLI/WHO
workshop report. Available at: http://www.ginasthma.org; 2010.
18. O’Hanlon R, O’Shea P, Ledwidge M, O’Loughlin C, Lange S, Conlon C, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail. 2007;13:50-5.
19. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377-81. 20. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced
ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993;16:5-40. 21. Maak CA, Tabas JA, McClintock DE. Should acute treatment with inhaled beta agonists be withheld
from patients with dyspnea who may have heart failure? J Emerg Med. 2011;40:135-45.
22. Perez-Padilla R, Hallal PC, Vazquez-Garcia JC, Muino A, Maquez M, Lopez MV, et al. Impact of bronchodilator use on the prevalence of COPD in population-based samples. Copd. 2007;4:113-20. 23. Hanania NA, King MJ, Braman SS, Saltoun C, Wise RA, Enright P, et al. Asthma in the elderly: Current
understanding and future research needs--a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011;128:S4-24.
6
24. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948-68.
25. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. J Am Coll Cardiol. 2011;57:2127-38.
26. Hanania NA, Sharafkhaneh A, Celli B, Decramer M, Lystig T, Kesten S, et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011;12:6. 27. Mentz RJ, Fiuzat M, Kraft M, Lindenfeld J, O’Connor CM. Bronchodilators in heart failure patients with
COPD: is it time for a clinical trial? J Card Fail. 2012;18:413-22.
28. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309-21.
29. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama. 2008;300:1439-50.
30. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. Bmj. 2011;342:d3215.
31. Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events?: a synthesis of the available evidence. Drugs. 2009;69:2025-33.
32. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium--the FDA’s conclusions. N Engl J Med. 2010;363:1097-9.
Armine G. Minasian Frank J.J. van den Elshout P.N. Richard Dekhuijzen Petra J.E. Vos
Frank F. Willems
Paul J.P.C. van den Bergh Yvonne F. Heijdra
Heart Lung. 2013;42:388-9.